Equities

Akums Drugs and Pharmaceuticals Ltd

Akums Drugs and Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)857.10
  • Today's Change0.70 / 0.08%
  • Shares traded43.12k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Oct 11 2024 11:14 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Akums Drugs and Pharmaceuticals Limited is an India-based pharmaceutical contract development and manufacturing company. It offers a comprehensive range of pharmaceutical products and services in India and overseas. It is focused on providing end-to-end product development and manufacturing solutions to its clients. Its segments include Contract Development and Manufacturing Operations (CDMO), Active Pharmaceutical Ingredient (API) and Branded and Generic formulations. CDMO segment includes the formulation research and development, preparation and regulatory filing of dossiers, manufacturing formulations on a contract basis, job work and testing services. API segment is engaged in the manufacture and sale of key starting materials, Intermediate and API products. Branded and Generic formulations segment is engaged in marketing and distribution of branded and generic pharmaceutical formulations. It has manufactured 4,146 commercialized formulations across over 60 dosage forms.

  • Revenue in INR (TTM)--
  • Net income in INR--
  • Incorporated2004
  • Employees7.39k
  • Location
    Akums Drugs and Pharmaceuticals LtdMangolpuri Ind. AreaPhase-I, Plot No. 131 to 133, Block-CNEW DELHI 110034IndiaIND
  • Phone+91 1 147511000
  • Fax+91 1 127023256
  • Websitehttps://www.akums.in/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Shilpa Medicare Ltd11.84bn447.57m85.31bn931.00174.64--55.737.215.005.00133.55--------12,716,850.00--2.84--3.6565.1960.083.797.03--1.56--10.769.669.44198.15-22.26-9.26--
Procter & Gamble Health Ltd11.51bn2.01bn86.90bn1.41k43.2616.1538.057.55121.01121.01693.20324.241.212.7111.45--21.21--29.28--71.29--17.46--1.90386.940.0175---6.37---12.42------
F D C Ltd20.45bn3.14bn87.30bn6.66k27.91--24.554.2719.2119.21124.56--------3,070,786.00--12.05--13.7365.5561.5415.3715.85--75.15--1.098.9212.2457.3012.4516.93--
Blue Jet Healthcare Ltd6.95bn1.57bn90.75bn447.0057.64--49.6113.069.089.0840.07--------15,547,110.00--------55.54--22.65----124.37-----1.30--2.33------
Sanofi Consumer Healthcare India Ltd8.01bn2.31bn112.90bn--48.9461.1648.1814.10100.17100.17347.6780.15----------------71.64--28.81--2.273,260.000.0986--------------
Marksans Pharma Ltd22.68bn3.34bn131.03bn2.00k39.22--31.615.787.377.3750.09--------11,339,960.00--14.62--18.5253.3950.5214.7114.03--32.19--6.1717.5616.8417.8032.6273.8664.38
Akums Drugs and Pharmaceuticals Ltd-100.00bn-100.00bn134.90bn7.39k------------------------------------------------14.32---104.25------
Strides Pharma Science Ltd42.09bn-475.19m143.40bn3.07k----103.813.41-5.440.4871460.14--------13,731,270.00---1.68---2.9760.1851.39-1.68-3.36--1.24----9.8313.2143.57---18.52-3.58
Glenmark Life Sciences Ltd22.93bn4.47bn144.34bn2.01k32.36--28.756.2936.4136.41186.81--------11,387,190.00--18.28--29.9954.5853.4019.4920.23--389.45--26.375.6420.830.84119.2169.11--
Caplin Point Laboratories Ltd17.58bn4.78bn144.91bn859.0030.42--26.838.2462.6762.67230.62--------20,462,630.00--19.83--22.8258.4153.3827.4325.39--1,525.59--9.0615.5021.1721.4820.9517.4717.84
Granules India Ltd47.01bn4.92bn146.35bn4.12k29.76--20.823.1120.2920.29193.87--------11,403,970.00--10.68--16.1856.8948.8310.4711.82--6.95--8.96-0.12314.61-21.5411.386.388.45
Wockhardt Ltd28.93bn-3.43bn152.91bn2.39k------5.29-23.75-23.75199.60--------12,084,380.00---4.56---8.2958.6655.26-12.17-12.70--0.0764----5.55-4.7317.17---4.71--
Sanofi India Ltd23.83bn4.30bn159.26bn2.17k37.0623.2634.036.68186.62229.861,034.61297.261.672.7315.6010,960,440.0030.0822.4257.5530.2155.9555.5218.0421.030.8140435.860.0313135.492.920.573-2.859.64-10.3414.73
Jubilant Pharmova Ltd68.48bn5.53bn181.53bn995.0032.88--19.492.6534.8634.86432.21--------68,821,100.00--2.96--3.5568.1368.478.015.13--2.34--24.736.70-5.95226.43-33.086.482.13
Neuland Laboratories Ltd.16.35bn3.36bn182.80bn1.65k54.39--45.8711.18261.94261.941,274.50--------9,922,259.00--9.25--12.7153.3247.8120.5511.99--29.52--7.1330.8418.5183.5178.7617.8863.45
Eris Lifesciences Ltd22.62bn3.80bn188.70bn3.08k49.67--30.918.3427.9127.91166.06--------7,344,939.00--13.42--16.8078.6879.9817.3624.96--4.20----19.2315.392.576.1527.72--
Data as of Oct 11 2024. Currency figures normalised to Akums Drugs and Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.